All Stories

  1. Diabetic Cardiomyopathy: Clinical and Metabolic Approach
  2. Electrocardiographic criteria which have the best prognostic significance in hypertensive patients with echocardiographic hypertrophy of left ventricle: 15‐year prospective study
  3. Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines
  4. Impact of metabolic syndrome on clinical severity and long-term prognosis in patients with myocardial infarction with ST-segment elevation
  5. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits
  6. PROGNOSTIC SIGNIFICANCE OF VISIT-TO-VISIT VARIABILITY, MEAN AND MAXIMUM BLOOD PRESSURE IN TREATED HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK
  7. Significance of asymptomatic hyperuricemia in patients after coronary events
  8. A Critical Approach of Guideline Therapeutic Recommendations for NAFLD
  9. Predictive value of metabolic syndrome definitions in patients with myocardial infarction with ST segment elevation – are they all the same?
  10. Patient with coronary artery disease and hypertension
  11. QTc dispersion and Cornell duration product can predict 10-year outcomes in hypertensive patients with left ventricular hypertrophy
  12. THE EFFECT OF DEGREE AND TYPE OF LEFT VENTRICULAR HYPERTROPHY ON VENTRICULAR ARRHYTHMIAS IN HYPERTENSION
  13. [OP.7B.07] FIFTEEN-YEAR PROGNOSTIC SIGNIFICANCE OF ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION
  14. [PP.01.19] PREDICTORS OF CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK
  15. [PP.11.34] THE PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH HYPERTENSION AND ITS IMPACT ON ASYMPTOMATIC CAROTID ATHEROSCLEROSIS
  16. [PP.05.12] SUBCLINICAL ORGAN DAMAGE IN HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK – FACTORS CONTRIBUTING TO THE CHANGE OF LEFT VENTRICULAR MASS AND CAROTID INTIMA MEDIA THICKNESS
  17. [PP.18.03] THE IMPACT OF ARTERIAL HYPERTENSION ON MORTALITY IN PATIENTS WITH MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION
  18. [PP.29.11] METABOLIC SYNDROME AS THE PREDICTOR OF NEW CARDIOVASCULAR EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION
  19. [PP.33.01] EVALUATION OF HYPERTENSIVE PATIENTS
  20. [PP.33.06] SUBCLINICAL ORGAN DAMAGE IN HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK
  21. [PP.36.06] THE IMPACT OF SERUM URIC ACID ON ASYMPTOMATIC CAROTID ATHEROSCLEROSIS AND RENAL DISEASE IN HYPERTENSIVE PATIENTS
  22. 4B.09
  23. PP.04.19
  24. Motivation and job satisfaction of health workers in a specialized health institution in Serbia
  25. Association of the thickness of carotid intima-media complex and ancle brachial index with coronary disease severity
  26. Impact of depression on sexual dysfunction and HRQoL in CAD patients
  27. Prevalence of arterial hypertension in Serbia
  28. Predictive value of noninvasive markers of atherosclerosis for cardiovascular morbidity and mortality in patients with coronary artery disease (4 years follow-up study)
  29. Eleven years of follow-up of patients with hypertensive left ventricular hypertrophy
  30. Health-related quality of life in patients with coronary artery disease after coronary revascularization
  31. Relation between bone density and certain parameters of lipid status in postmenopausal women
  32. Predictive value of non-invasive parameters in patients with left ventricular hypertrophy during a five-year follow-up period
  33. The clinical significance of antibody determination to cyclic citrullinated peptides in systemic sclerosis
  34. GENDER SPECIFIC PROGNOSTIC DIFFERENCES IN REGARD TO THE REGRESSION OF HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY (12 YEARS FOLLOW-UP STUDY)
  35. NINE YEARS FOLLOW-UP OF PATIENTS WITH HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY AND PREDICTIVE VALUE OF NON-INVASIVE PARAMETERS
  36. THE INFLUENCE OF METABOLIC SYNDROME ON THE OCCURRENCE AND SEVERITY OF CAROTID ATHEROSCLEROSIS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
  37. Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction?
  38. EFFECTS OF THE EARLY ONE YEAR TREATMENT IN HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY AND SIGNIFICANCE ON CARDIOVASCULAR EVENTS IN THE FUTURE: PP.22.373
  39. METABOLIC SYNDROME AND ATHEROSCLEROSIS OF CAROTID ARTERIES IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY: PP.2.79
  40. PREDICTIVE VALUE OF NON-INVASIVE PARAMETERS DURING EIGHT YEARS FOLLOW-UP OF PATIENTS WITH HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY: PP.22.378
  41. THE AFFECT OF THE REGRESSION OF THE LEFT VENTRICULAR HYPERTROPHY OF THE FUNCTIONAL CAPACITY IN HYPERTENSIVE PATIENTS: PP.35.487
  42. Five years prognosis of patients with arterial hypertension and left ventricular hypertrophy
  43. Effects of balneotherapy on the reactants of acute inflammation phase in Ankylosing spondylitis
  44. Evaluation of myocardial function in the presence of left ventricular hypertrophy in athletes and hypertensive patients
  45. Correlation between 24-hour profile of blood pressure and ventricular arrhythmias and their prognostic significance in patients with arterial hypertension
  46. Prognostic value of QTc interval dispersion changes during exercise testing in hypertensive men
  47. Carotid atherosclerosis associated to metabolic syndrome and ischemic heart disease in hypertensive patients with left ventricular hypertrophy
  48. Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients
  49. 24-HOUR PULSE PRESSURE AT HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
  50. IMPACT OF LEFT VENTRICULAR HYPERTROPHY ON REGIONAL MYOCARDIAL VELOCITIES IN ATHLETES AND HYPERTENSIVES HEART
  51. 717 Quantification of regional myocardial function detects super-silent myocardial ischaemia in diabetic patients
  52. The relationship between ventricular arrhythmias, heart rate variability and ventricular systolic function